This article was originally published in The Rose Sheet
Executive SummarySpecialty fragrance ingredient sales grew double-digits in the first half, fragrance and flavors manufacturer reports Aug. 10. However, total fragrance division sales were flat in local currency and declined 2% in Swiss Francs to $439 mil. (CHF1=$.79). Excluding effects of discontinued ingredients, revenues would have increased 6% in local currency, or 4% in Swiss Francs, firm points out. Operating profit in the division was up 2% to $73 mil. Group sales increased 3.2% in local currencies and 1.5% in Swiss Francs to $1.1 bil. Net income in the half grew 32% to $174.4 mil. and operating profit advanced 12% to $224.3 mil. on a comparable basis...
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.